Teva is most at risk in the opioid trials, says Vanity Fair's McLean

Opening statements began Monday in the nation's first federal trial over the opioid crisis. Beth McLean, Vanity Fair contributing editor, joins "Squawk Box" to discuss.
04:03
Mon, Oct 21 20197:34 AM EST